A drug free solution for improving the quality of life of fibromyalgia patients (Fibrepik): study protocol of a multicenter, randomized, controlled effectiveness trial

Emilie Chipon, Jean-Luc Bosson, Laure Minier, Anne Dumolard, Antoine Vilotitch, David Crouzier, Caroline Maindet, Emilie Chipon, Jean-Luc Bosson, Laure Minier, Anne Dumolard, Antoine Vilotitch, David Crouzier, Caroline Maindet

Abstract

Background: Fibromyalgia is a form of chronic widespread pain that is defined as a syndrome of chronic symptoms of moderate to severe intensity, including diffuse pain, fatigue, sleep disturbance, cognitive impairment, and numerous somatic complaints. To date, there is no specific drug treatment for fibromyalgia but only symptomatic treatments. A drug free solution based on a wristband that emits millimeter waves associated with a therapeutic coaching program was developed. The application of millimeter waves on an innervated area has been described to have a neuromodulating effect, due to endorphin release stimulation and parasympathetic activation. Coaching is carried out to improve the patient's adherence and to increase compliance and effectiveness of the treatment. Regular use of this solution by fibromyalgia patients is expected to improve sleep quality, reduce anxiety and pain levels, and, at the end, increase the quality of life.

Methods: This trial is performed over 8 French inclusion centers for a total of 170 patients. The effectiveness of the solution is evaluated according to the primary objective, the improvement of the quality of life measured through the dedicated Fibromyalgia Impact Questionnaire after 3 months. Patients are randomized in two groups, Immediate or Delayed. The Immediate group has access to the solution just after randomization in addition to standard care, while Delayed has access to the standard of care and waits for 3 months to have the solution. The purpose of this methodology is to limit deception bias and facilitate inclusion. The solution consists in using the device for three sessions of 30 min per day and four coaching sessions spread over the first 2 months of wristband usage.

Discussion: The objective is to confirm the effect of the integrative approach based on endorphin stimulation and a therapeutic coaching program in nociplastic pain and specifically for the patient suffering from fibromyalgia. If the effectiveness of the solution is demonstrated, we will be able to respond to the demand of fibromyalgia patients for access to an effective non-medicinal treatment to improve their quality of life.

Trial registration: ClinicalTrials.gov NCT05058092.

Keywords: Endorphins; Fibromyalgia; Holistic approach; Millimeter waves; Pain; Quality of life; Sleep disturbances.

Conflict of interest statement

CM is a member of the scientific advisory board of Remedee Labs. The other authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Presentation of the study design

References

    1. Benlidayi IC. Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatol Int. 2019;39(5):781–791. doi: 10.1007/s00296-019-04251-6.
    1. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8(1):1–11. doi: 10.1186/1471-2474-8-27.
    1. Clauw DJ. Mayo Clinic Proceedings Elsevier. 2015. Fibromyalgia and related conditions; pp. 680–692.
    1. Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008;73(1):114–120. doi: 10.1016/j.pec.2008.06.005.
    1. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318–328. doi: 10.1136/annrheumdis-2016-209724.
    1. Radzievsky AA, Rojavin MA, Cowan A, Alekseev SI, Radzievsky AA, Ziskin MC. Peripheral neural system involvement in hypoalgesic effect of electromagnetic millimeter waves. Life Sci. 2001;68(10):1143–1151. doi: 10.1016/S0024-3205(00)01016-X.
    1. Radzievsky AA, Gordiienko OV, Alekseev S, Szabo I, Cowan A, Ziskin MC. Electromagnetic millimeter wave induced hypoalgesia: Frequency dependence and involvement of endogenous opioids. Bioelectromagnetics. 2008;29(4):284–295. doi: 10.1002/bem.20389.
    1. Rojavin MA, Ziskin MC. Electromagnetic millimeter waves increase the duration of anaesthesia caused by ketamine and chloral hydrate in mice. Int J Radiat Biol. 1997;72(4):475–480. doi: 10.1080/095530097143248.
    1. Radzievsky AA, Rojavin MA, Cowan A, Alekseev SI, Ziskin MC. Hypoalgesic effect of millimeter waves in mice: Dependence on the site of exposure. Life Sci. 2000;66(21):2101–2111. doi: 10.1016/S0024-3205(00)00536-1.
    1. Radzievsky AA, Gordiienko OV, Cowan A, Alekseev SI, Ziskin MC. Millimeter-wave-induced hypoalgesia in mice: dependence on type of experimental pain. IEEE Transact Plasma Sci. 2004;32(4):1634–1643. doi: 10.1109/TPS.2004.830972.
    1. Rojavin MA, Radzievsky AA, Cowan A, Ziskin MC. Pain relief caused by millimeter waves in mice: results of cold water tail flick tests. Int J Radiat Biol. 2000;76(4):575–579. doi: 10.1080/095530000138592.
    1. Radzievsky AA, Rojavin MA, Cowan A, Ziskin MC. Suppression of pain sensation caused by millimeter waves: a double-blinded, cross-over, prospective human volunteer study. Anesth Analg. 1999;88(4):836–840. doi: 10.1213/00000539-199904000-00029.
    1. Usichenko TI, Herget HF. Treatment of chronic pain with millimetre wave therapy (MWT) in patients with diffuse connective tissue diseases: a pilot case series study. Eur J Pain. 2003;7(3):289–294. doi: 10.1016/S1090-3801(02)00125-8.
    1. Usichenko TI, Ivashkivsky OI, Gizhko VV. Treatment of rheumatoid arthritis with electromagnetic millimeter waves applied to acupuncture points-a randomized double blind clinical study. Acupuncture Electro-Ther Res. 2003;28(1–2):11–18. doi: 10.3727/036012903815901723.
    1. Usichenko TI, Edinger H, Gizhko VV, Lehmann C, Wendt M, Feyerherd F. Low-intensity electromagnetic millimeter waves for pain therapy. Evid Based Complement Alternat Med. 2006;3(2):201–207. doi: 10.1093/ecam/nel012.
    1. Moazezi Z, Hojjati SMM, Ayrapetyan S. Low Intensity Millimeter Wave as a Potential Tool in Treatment of Diabetic Sensorymotor Polyneuropathy. Int Dental Med Disord. 2008;1(1).
    1. Egawa M, Yoshimatsu H, Bray GA. Effect of beta-endorphin on sympathetic nerve activity to interscapular brown adipose tissue. Am J Phys Regul Integr Comp Phys. 1993;264(1):R109–R115.
    1. Haddad GG, Jeng HJ, Lai TL. Effect of endorphins on heart rate and blood pressure in adult dogs. Am J Phys Heart Circ Phys. 1986;250(5):H796–H805.
    1. Holaday JW. Cardiovascular Effects of Endogenous Opiate Systems. Annu Rev Pharmacol Toxicol. 1983;23(1):541. doi: 10.1146/annurev.pa.23.040183.002545.
    1. Wong TM, Shan J. Modulation of sympathetic actions on the heart by opioid receptor stimulation. J Biomed Sci. 2001;8(4):299–306. doi: 10.1007/BF02258370.
    1. Drolet G, Dumont IC, Gosselin I, Kinkead R, Laforest S, Troti’Ier O. Role of endogenous opioid system in the regulation of the stress response. Prog Neuro-Psychopharmacol Biol Psychiatry. 2001;25(4):729–741. doi: 10.1016/S0278-5846(01)00161-0.
    1. Miglis MG. Chapter 12 - Sleep and the Autonomic Nervous System. In: Miglis MG, editor. Sleep and Neurologic Disease. San Diego: Academic Press; 2017. pp. 227–244.
    1. Moldofsky H. The significance of the sleeping–waking brain for the understanding of widespread musculoskeletal pain and fatigue in fibromyalgia syndrome and allied syndromes. Joint Bone Spine. 2008;75(4):397–402. doi: 10.1016/j.jbspin.2008.01.021.
    1. Affleck G, Urrows S, Tennen H, Higgins P, Abeles M. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. Pain. 1996;68(2):363–368. doi: 10.1016/S0304-3959(96)03226-5.
    1. Ashburn MA, Staats PS. Management of chronic pain. Lancet. 1999;353(9167):1865–1869. doi: 10.1016/S0140-6736(99)04088-X.
    1. Versluis A, Verkuil B, Spinhoven P, van der Ploeg MM, Brosschot JF. Changing Mental Health and Positive Psychological Well-Being Using Ecological Momentary Interventions: A Systematic Review and Meta-analysis. J Med Internet Res. 2016;18(6):e5642. doi: 10.2196/jmir.5642.
    1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319–329. doi: 10.1016/j.semarthrit.2016.08.012.
    1. Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry. 2013;12(2):92–98. doi: 10.1002/wps.20050.
    1. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal Clinically Important Difference in the Fibromyalgia Impact Questionnaire. J Rheumatol. 2009;36(6):1304–1311. doi: 10.3899/jrheum.081090.
    1. Perrot S, Dumont D, Guillemin F, Pouchot J, Coste J. Research FG for Q of L. Quality of life in women with fibromyalgia syndrome: validation of the QIF, the French version of the fibromyalgia impact questionnaire. J Rheumatol. 2003;30(5):1054–1059.
    1. Buysse DJ, Reynolds CF, III, Monk TH, Berman SR, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. doi: 10.1016/0165-1781(89)90047-4.
    1. Lepine JP, Godchau M, Brun P. Anxiety and depression in inpatients. Lancet. 1985;2(8469–70):1425–1426. doi: 10.1016/S0140-6736(85)92589-9.
    1. Smets EMA, Garssen B, Bonke B, De Haes JCJM. The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–325. doi: 10.1016/0022-3999(94)00125-O.
    1. Group TE EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208. doi: 10.1016/0168-8510(90)90421-9.
    1. Cleland CL, Hunter RF, Kee F, Cupples ME, Sallis JF, Tully MA. Validity of the Global Physical Activity Questionnaire (GPAQ) in assessing levels and change in moderate-vigorous physical activity and sedentary behaviour. BMC Public Health. 2014;14(1):1255. doi: 10.1186/1471-2458-14-1255.
    1. Rampakakis E, Ste-Marie PA, Sampalis JS, Karellis A, Shir Y, Fitzcharles MA. Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open. 2015;1(1):e000146. doi: 10.1136/rmdopen-2015-000146.
    1. Lallemand C, Koenig V. Proceedings of the European Conference on Cognitive Ergonomics 2017. New York: Association for Computing Machinery; 2017. How Could an Intranet be Like a Friend to Me? Why Standardized UX Scales Don’t Always Fit; pp. 9–16.
    1. Bennett RM. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol. 2005;23(Suppl. 39):S154–S162.
    1. Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397(10289):2098–2110. doi: 10.1016/S0140-6736(21)00392-5.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться